This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

Impact · against what's priced in

TGTX shows strong commercial traction for BRIUMVI, but recent guidance disappointments have already weighed heavily on the stock price. An $8 million institutional entry provides a positive signal, but the primary catalyst remains whether the company can exceed its 2026 revenue target of $875M-$900M.

TGTX+0.30

No priced-in read yet